Advertisment

Promising Results from Phase I Trial of Weight Management Agent Maridebart Cafraglutide

author-image
Mason Walker
New Update
NULL

Promising Results from Phase I Trial of Weight Management Agent Maridebart Cafraglutide

Advertisment

A recent phase I human trial of an investigational weight management agent, maridebart cafraglutide, evoked promising results, with the highest dose group experiencing a 14.5% body weight loss by day 85. This experimental drug is currently under development by Amgen and has shown significant potential in the realm of weight loss and management.

Advertisment

Understanding Maridebart Cafraglutide

Maridebart cafraglutide acts as an inhibitor of the gastric inhibitory polypeptide receptor (GIPR), and an activator of glucagon-like peptide 1 (GLP-1) receptor. These actions result in a decrease in food intake and an increase in energy expenditure, leading to weight loss. This promising candidate for obesity and related metabolic disorders is designed for GIPR/GLP-1R bispecific modulation, showing persistent pharmacokinetic properties and dose-dependent effects on weight reduction and glucose levels.

Study Results and Implications

Advertisment

The trial demonstrated durable weight loss, with the high-dose group maintaining an 11.2% weight loss from baseline at 150 days following the last dose. The study also revealed dose-dependent reductions in BMI and fasting glucose, as well as a decrease in HbA1c levels, indicators of improved metabolic health. The safety profile of the drug was deemed acceptable, with adverse events primarily gastrointestinal-related, the most common of which was nausea.

Intra-Patient Dose-Escalation-Based Regimens

The study suggested that intra-patient dose-escalation-based regimens may offer an advantage in decreasing the first-dose effect. This could potentially allow patients to wean onto lower or less frequent doses over time, which could improve compliance and long-term effectiveness of the weight management treatment.

Advertisment

Comparisons with Other Weight Loss Drugs

Other weight-loss drugs, including Wegovy, Tirzepatide, and Ozempic have also been discussed in the news. While these drugs have shown efficacy, the preliminary results of the maridebart cafraglutide trials indicate that it could provide longer-lasting weight loss. This could position maridebart cafraglutide as a key player in the obesity care space.

Future Plans and Expectations

Amgen plans to release topline data from the phase II study of maridebart cafraglutide later this year. If these trials yield positive results, it could pave the way for maridebart cafraglutide to make a significant impact in the treatment of obesity and related metabolic disorders. However, further research is necessary to confirm the drug’s efficacy and safety profile in a larger population and over a longer period.

Amgen's shares rose 1.21% to $327.11 premarket following the release of the promising early data. The company is actively recruiting for a Clinical Research Medical Director to lead the global development program for AMG 133, indicating a strong commitment to the development and success of maridebart cafraglutide.

Advertisment
Chat with Dr. Medriva !